Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.
Journal Information
Full Title: Infect Drug Resist
Abbreviation: Infect Drug Resist
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pharmacology & Pharmacy
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosures: Dr Steigbigel receives research support from Merck Research Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, and NexBio Pharmaceuticals. He is on the speakers bureau for Merck, as well as the advisory board for Boehringer Ingelheim. Dr Chirch has no conflicts of interest to declare."
"Disclosures: Dr Steigbigel receives research support from Merck Research Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, and NexBio Pharmaceuticals. He is on the speakers bureau for Merck, as well as the advisory board for Boehringer Ingelheim. Dr Chirch has no conflicts of interest to declare."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025